GlassScriptPhysician profile
Rhonda E Alkatib
NPI 1417363086
$19,995.85
in general payments reported to CMS, 2019-2025
39 companies · $3,585 in 2025
The $3,585 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $409 · 2021: $2,185 · 2022: $2,775 · 2023: $2,271 · 2024: $8,014 · 2025: $3,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,326 · Consulting Fee: $4,625 · Travel and Lodging: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,325.76 |
| Consulting Fee | $4,625.00 |
| Travel and Lodging | $919.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,478.11 | 2021-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,837.71 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,165.94 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,568.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $644.89 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $601.57 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $563.22 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Amgen INC. | $562.17 | 2021-2025 | Tezspire |
| Pfizer INC. | $467.63 | 2021-2024 | |
| Lilly USA, LLC | $370.72 | 2020-2025 | Ebglyss, Taltz |
| Incyte Corporation | $351.15 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $338.38 | 2021-2025 | |
| Csl Behring | $327.67 | 2020-2025 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.21 | 2020-2023 | Spiriva Respimat |
| Kaleo, INC. | $272.25 | 2020-2023 | Auvi-Q |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $227.88 | 2022-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $225.05 | 2025 | Neffy |
| Leo Pharma INC. | $220.56 | 2023-2025 | Adbry, Anzupgo |
| Genentech, INC. | $154.95 | 2021-2022 | |
| Octapharma USA, INC. | $150.40 | 2021-2022 | |
| Alk-Abello, INC | $128.52 | 2020-2025 | Odactra, Ragwitek, Grastek |
| Biocryst US Sales Co., LLC | $123.62 | 2022-2025 | Orladeyo |
| Optinose US, INC. | $121.09 | 2021-2024 | |
| Greer Laboratories, INC. | $111.73 | 2024-2025 | Palforzia, Oralair |
| Shire North American Group INC | $105.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $102.70 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $87.47 | 2020-2023 | |
| Abbvie INC. | $63.81 | 2022-2023 | Rinvoq |
| Sanofi-Aventis U.S. LLC | $53.06 | 2021 | |
| Ionis Pharmaceuticals, INC. | $52.32 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $50.06 | 2023-2024 | Ruconest |
| Phadia US INC. | $49.46 | 2021-2023 | Immunocap |
| Horizon Therapeutics Plc | $22.74 | 2019 | |
| Hikma Pharmaceuticals USA | $21.11 | 2023 | Ryaltris |
| Cycle Pharmaceuticals INC | $20.27 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $16.86 | 2023 | |
| Azurity Pharmaceuticals, INC. | $16.14 | 2025 | Alvesco |
| Arcutis Biotherapeutics, INC. | $14.24 | 2025 | Zoryve |
| Bio Products Laboratory USA, INC. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Alkatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.